Sacral Neuromodulation — Procedure Guide, Recovery & Risks | MyMedicPlus

Sacral neuromodulation (SNM), also known as sacral nerve stimulation (SNS), is a reversible neuromodulation therapy that delivers programmable low-amplitude electrical pulses to the S3 sacral nerve root via a surgically implanted lead electrode connected to an implantable pulse generator (IPG) placed subcutaneously in the upper buttock. The sacral nerve roots (S2–S4) regulate the bladder, sphincter, and pelvic floor through complex neural circuits. SNM modulates — rather than simply blocks or stimulates — these neural pathways, normalising aberrant sensory and motor signals responsible for overactive bladder symptoms and faecal incontinence.

The first-generation Medtronic InterStim System has been used since 1997 and has more than 300,000 implants worldwide. The second-generation InterStim II (smaller IPG) and the rechargeable InterStim Micro system allow MRI compatibility and longer battery life. The procedure involves a minimally invasive two-stage implant with a test stimulation phase allowing patients to experience the therapeutic effect before committing to permanent implantation — providing a unique 'try before you buy' advantage over most other surgical interventions. Patient-controlled adjustment of stimulation parameters via a handheld programmer allows optimisation without further procedures. The procedure was first approved by the FDA in 1997 and has since been implanted in over 300,000 patients globally.

Sacral neuromodulation is indicated for patients with refractory overactive bladder (OAB) — characterised by urgency, urinary frequency (greater than 8 voids per 24 hours), and urgency urinary incontinence — that has not responded adequately to first-line behavioural therapy (bladder training, fluid management, pelvic floor exercises) and second-line pharmacological therapy (anticholinergic medications such as solifenacin or oxybutynin, or the beta-3 agonist mirabegron) at adequate doses for at least 4–8 weeks.

A second major indication is non-obstructive urinary retention (inability to void despite a structurally normal urethra and bladder neck), where SNM has demonstrated efficacy in restoring spontaneous voiding and reducing or eliminating the need for clean intermittent self-catheterisation (CISC) in approximately 70% of appropriately selected patients.

Faecal incontinence that has failed conservative management (dietary modification, bulking agents, biofeedback) and minor procedures is a third major indication, with SNM recommended ahead of sphincter surgery in most international guidelines. Contraindications include bilateral S3 pathology, pregnancy, inability to operate the device, and need for frequent MRI scanning (though MRI-conditional devices are now available for most patients).

The SNM procedure is performed in two stages to allow a mandatory trial period before permanent implantation.

Stage 1 — Percutaneous Nerve Evaluation (PNE) or Staged Lead Implant: The patient lies prone under fluoroscopic guidance. A foramen needle is directed into the S3 sacral foramen (identified by the third sacral foramen, two finger-breadths lateral to the midline of the sacrum). Electrical stimulation confirms correct placement by eliciting bellows contraction of the ipsilateral perineum and plantar flexion of the big toe (S3 motor response) with a sensation of pressure/tingling in the perineum or vagina. A quadripolar tined (barbed) lead electrode is then deployed and fixed with tines to prevent migration. The lead is tunnelled subcutaneously and connected to an external neurostimulator worn for a 2–4 week test period.

During the test phase, the patient keeps a bladder diary recording void frequency, urgency episodes, incontinence episodes, and pad usage. A greater than 50% improvement in at least one key symptom (urgency episodes, void frequency, incontinence pad usage) constitutes a positive response.

Stage 2 — Permanent Implant: Under general or spinal anaesthesia, the external lead connector is internalised and connected to the IPG, which is implanted in a subcutaneous pocket created in the ipsilateral upper buttock. Stimulation parameters are programmed before discharge and optimised at 2-week and 6-week follow-up visits. The entire procedure takes 30–60 minutes at each stage.

Stage 1 is performed as day surgery; patients return home with the external stimulator and bladder diary. During the 2–4 week test period, patients avoid vigorous activity, bending, and heavy lifting to prevent lead migration. Waterproof dressings protect the exit site. Patients are reviewed remotely or in clinic during the test period.

After Stage 2 permanent implantation, patients are discharged the same day or after one overnight stay. Sitting on hard surfaces is avoided for one week and the buttock wound is kept dry for two weeks. Strenuous activity and heavy lifting are avoided for 4 weeks to allow the IPG pocket to heal securely. Stimulation parameters are adjusted at 2-week and 6-week appointments based on bladder diary data and patient-reported symptoms.

Long-term, the IPG battery lasts 5–7 years (non-rechargeable) or up to 15 years (rechargeable Micro). Battery replacement requires a minor outpatient procedure under local anaesthesia to replace the IPG while retaining the lead. Patients with MRI-conditional devices can undergo body MRI under specific protocols and require programming adjustments around the scan.

Lead migration is the most common hardware complication, occurring in 10–15% of patients, and may require revision surgery under fluoroscopic guidance to reposition the electrode. Infection at the implant site occurs in 3–5% of cases; superficial infections are treated with antibiotics, but deep infections may necessitate complete device removal. Seroma (fluid collection) around the IPG is common, typically resolving spontaneously within weeks.

Pain at the IPG site occurs in 5–15% of patients, sometimes requiring device repositioning. Lead fracture from repeated bending stress occurs in approximately 5% of cases over 5 years. Device malfunction, component failure, and battery depletion are managed with revision or replacement procedures. Stimulation-related side effects include unpleasant or painful sensations if parameters are incorrectly programmed — resolved by reprogramming — and temporary worsening of symptoms after parameter changes.

There is a 5–10% rate of surgical revision procedures at 5 years for various hardware-related reasons. Importantly, the device is fully explantable, and SNM can be abandoned without permanent harm if it ceases to be beneficial.

Published long-term data demonstrate that 70–85% of patients who complete Stage 1 testing achieve greater than 50% improvement in primary bladder or bowel symptoms, qualifying for permanent implantation. Of those who receive the permanent device, 60–70% maintain clinically meaningful improvement at 5-year follow-up.

For overactive bladder, the SNS Study (Siegel et al.) demonstrated sustained reduction in urgency incontinence episodes by more than 50% in 59% of patients at 5 years, with 41% achieving complete continence. Void frequency reduces by an average of 4–6 voids per day. For non-obstructive urinary retention, 70% of patients eliminate CISC entirely after SNM implant.

For faecal incontinence, SNM achieves greater than 50% reduction in incontinence episodes in 75–85% of patients at 3 years, with complete continence restored in 35–45%. The procedure avoids the morbidity of more invasive sphincter repair surgery and is reversible. Quality-of-life scores (SF-36, FIQL for bowel, IQOL for bladder) consistently show significant improvements. Given the high burden of OAB and faecal incontinence on daily life, work, and mental health, the psychological benefits of regaining bladder and bowel control are profound.